LGND 250117 135.00P (LGND250117P135000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

LGND250117P135000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 31 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Have Insiders Sold Ligand Pharmaceuticals Shares Recently?
Simply Wall StJan 1 07:24 ET
Insider Sale: Chief Financial Officer of $LGND (LGND) Sells 2,104 Shares
Quiver QuantitativeDec 26, 2024 20:45 ET
Earnings Grew Faster Than the Notable 60% Return Delivered to Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Over the Last Year
Simply Wall StDec 23, 2024 13:26 ET
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $135
Moomoo NewsDec 23, 2024 07:33 ET · Ratings
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Dow JonesDec 16, 2024 09:52 ET · Ratings
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
Moomoo NewsDec 16, 2024 06:31 ET · Ratings

Comments

Iwill TradeScared

Oct 26, 2024 01:18

$Ligand Pharmaceuticals (LGND.US)$ $125 IN ~$149 OUT in future easy stress free money….

Moomoo AI

Feb 29, 2024 09:33

Ligand Pharmaceuticals' key financial indicators are inconsistent, raising questions about the sustainability of its current share price momentum. The company's low ROE and declining net income, along with shrinking earnings despite retaining all profits, suggest potential issues with its business operations or capital allocation.

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Kevin Travers

Feb 27, 2024 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Moomoo AI

Jan 25, 2024 06:30

Insider selling at Ligand Pharmaceuticals, particularly at current share price, raises caution. Modest insider ownership indicates some alignment with shareholders, but lack of recent insider transactions doesn't raise immediate concerns.

Several Ligand Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal

Moomoo AI

Dec 20, 2023 08:52

Ligand Pharmaceuticals' high P/E ratio may be plausible with outstanding growth. Its promising future earnings outlook may prevent investors from selling stocks. Unless earnings decline, the current P/E ratio could support the share price.

Investors Appear Satisfied With Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Prospects